ASCO 2025 ProstACT Global, phase 3 study of 177Lu-rosptamab + standard of care versus standard of care alone, metastatic castration-resistant prostate cancer (mCRPC).

Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic ...

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025, prostate cancer, radioligand therapy (RLT), Radioligand Therapies in Prostate Cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), 177Lu-PSMA-617.